Paul Delmar

4.1k citations

87 papers · 2.4k indexed · 1 hit paper · h-index 23

Impact in

Biological Psychiatry top 5%
Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology

Papers in

Statistics and Probability 17
- Statistical Methods in Clinical Trials 14
Physiology 24
- Alzheimer's disease research and treatments 22

Co-authors: Eric Van Cutsem Sanne de Haas Stefan Scherer Paulo Fontoura Gregory Klein Carsten Hofmann Mirjana Andjelković Niall C. Tebbutt
Journals: Alzheimer s & Dementia (23 papers)European Journal of Cancer (7 papers)Neurology (5 papers)Journal of Thoracic Oncology (3 papers)Pharmaceutical Statistics (3 papers)
Partner nations: Switzerland United Kingdom United States

In The Last Decade

Paul Delmar

80 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease 2017 · 411 citations

Peers

Countries citing papers authored by Paul Delmar

Since Specialization

Citations

This map shows the geographic impact of Paul Delmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Delmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Delmar more than expected).

Fields of papers citing papers by Paul Delmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Delmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Delmar. The network helps show where Paul Delmar may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul Delmar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Delmar Line = papers co-authored together Paul Delmar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease Alzheimer s & Dementia ·Gregory Klein, Gregory Szuladziński, Hasmulyadi Hasmulyadi, Abd ElAziz Barr, Tobias Bittner, Daria Rukina, Hyo Song Lee, Carsten Hofmann, Maddalena Marchesi, Siddharth S.M.P, Annisa Rakhmah, David J. Agnew, Yi Jen Chiu, Terrence Conway, Hubert Weibel, Paul Delmar, Hanno Svoboda, A. Shareef, Luka Kulic	2025	0
2	Biomarker treatment effects in two phase 3 trials of gantenerumab Alzheimer s & Dementia ·Tobias Bittner, Mattéo Tonietto, Gregory Klein, 林耀章, Velocity-Log Data, Nicola Voyle, Paul Delmar, Marzia A. Scelsi, Michel J. Drake, Subash Bhandari, Muhamed Baraković, Antonio Napolitano, Vanessa Franco, Women's Educational, Kaj Blennow, Frederik Barkhof	2025	2
3	Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD) Journal of Alzheimer s Disease ·Merçé Boada, Emmanuel Bukoma, Gesus Padilha, Siddharth S.M.P, F Frazhanet, Szofia Bullain, Julian Mora Chavez, В.Г. Воронина, Tobias Bittner, Paul Delmar, Gregory Klein, Carsten Hofmann, Geoffrey A. Kerchner, Janice Smith, Monika Baudler, Paulo Fontoura, Rachelle S. Doody	2024	0
4	Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer’s disease Alzheimer s & Dementia ·Emmanuel Bukoma, Szofia Bullain, Gesus Padilha, F Frazhanet, Julian Mora Chavez, Paul Delmar, Gregory Klein, Tobias Bittner, В.Г. Воронина, Janice Smith, Geoffrey A. Kerchner, Paulo Fontoura, Monika Baudler, Rachelle S. Doody	2023	3
5	Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease The Journal of Prevention of Alzheimer s Disease ·Chan Amy, Fiona McDougall, Lesley M. Butler, Paul Delmar, Nathalie Pross, Shanshan Qin, Lori McLeod, Xiaolei Zhou, Geoffrey A. Kerchner, Rachelle S. Doody	2022	48
6	Psychometric Properties of the Clinical Dementia Rating — Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population The Journal of Prevention of Alzheimer s Disease ·Fiona McDougall, Chris J. Edgar, Saeed Ghahremani Namain, Paul Delmar, Paulo Fontoura, Danielle Abi‐Saab, Chan Amy, Merçé Boada, Rachelle S. Doody	2021	31
7	Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies (S9.007) Neurology ·Gregory Klein, Paul Delmar, Sunita Rehal, Mirjana Andjelković, Danielle Abi‐Saab, Szofia Bullain, Nasrin Zandi Dashtebayaze, Monika Baudler, Paulo Fontoura, Rachelle S. Doody	2019	0
8	Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005) Neurology ·Gregory Klein, Paul Delmar, Carsten Hofmann, 谷口健次, Danielle Abi‐Saab, علي يعقوب, Monika Baudler, Jong-Ho Rha, Rachelle S. Doody	2018	3
9	A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease Alzheimer s Research & Therapy ·(unknown), Susanne Ostrowitzki, Robert Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelković, Bruno Dubois, Merçé Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura Hit paper breakdown →	2017	411
10	Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab Contemporary Clinical Trials Communications ·Paul Delmar, Francis Cabu, Lü Tian	2017	1
11	The novel bispecific monoclonal anti-VEGF/anti-Ang2 antibody RG7716 shows promise in wet age-related macular degeneration patients with suboptimal response to prior anti-VEGF monotherapy Investigative Ophthalmology & Visual Science ·Usha Chakravarthy, Dietmar Schwab, Patrick G. Cech, Andris Potrebko, Anne Boulay, Piotr Szczęsny, Paul Delmar, Jayashree Sahni	2016	1
12	Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-Inhibitor Treated Patients Value in Health ·HELEN M. CARROLL, 真美三木, Mathieu Coudert, Paul Delmar, Ursula Becker, Gracy Crane	2016	3
13	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations Journal of Thoracic Oncology ·Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, Tudor–Eliade Ciuleanu, Tony Mok, Martin Reck, Eng Huat Tan, Paul Delmar, Gaëlle Klingelschmitt, Gabriela Abrahão Allioni, Olivia Spleiss, Lin Wu, David S. Shames	2016	78
14	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Journal of Thoracic Oncology ·Denis Soulières, Fred R. Hirsch, Frances A. Shepherd, Walter Bordogna, Paul Delmar, David S. Shames, Barbara Klughammer	2015	18
15	A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015) Journal of Thoracic Oncology ·Tony Mok, В. А. Горбунова, Erzsébet Juhász, Olivia Eguiguren Istuany, Olga Burdaeva, С. В. Орлов, Chong‐Jen Yu, Venice Archer, Magalie Hilton, Paul Delmar, Céline Pallaud, Martin Reck	2014	39
16	Genetic markers of bevacizumab-induced hypertension Angiogenesis ·Diether Lambrechts, Matthieu Moisse, Paul Delmar, David W. Miles, Natasha B. Leighl, Bernard Escudier, Eric Van Cutsem, Aruna T. Bansal, Peter Carmeliet, Stefan Scherer, Sanne de Haas, Céline Pallaud	2014	22
17	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial Journal of Clinical Oncology ·Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang, Atsushi Ohtsu, Niall C. Tebbutt, Jianming Xu, Wei Peng Yong, Bernd Langer, Paul Delmar, Stefan Scherer, Manish A. Shah	2012	358
18	Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab Cancer Research ·Bart Claes, Paul Delmar, Betül T. Yesilyurt, Joke Reumers, Massimiliano Mazzone, Roland Devlieger, Hans Wildiers, Sanne de Haas, Peter Carmeliet, Eric Van Cutsem, Stefan Scherer, Diether Lambrechts	2012	138
19	Gene expression profiling on pre‐ and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma Head & Neck ·Fabienne Thomas, Paul Delmar, S. Vergèz, Philippe Rochaix, Isabelle Hennebelle, Patricia McLoughlin, A. Benlyazid, Jérôme Sarini, Jean‐Pierre Delord	2012	4
20	The Transcriptional Coactivator Peroxisome Proliferator-Activated Receptor (PPAR)[gamma] Coactivator-1[alpha] and the Nuclear Receptor PPAR[alpha] Control the Expression of Glycerol Kinase and Metabolism Genes Independently of PPAR[gamma] Activation in Human White Adipocytes Université Pierre et Marie CURIE (UPMC) ·Anne Mazzucotelli, Nathalie Viguerie, Claire Tiraby, Jean‐Sébastien Annicotte, Aline Mairal, Eva Klimčáková, Z Bartůnková, Paul Delmar, Sébastien Dejean, Geneviève Tavernier, Corinne Lefort, Juan Hidalgo, Thierry Pineau, Lluís Fajas, Karine Clément, Dominique Langin	2007	1

About Paul Delmar

Paul Delmar is a scholar working on Statistics and Probability, Physiology, Oncology, Psychiatry and Mental health and Pulmonary and Respiratory Medicine, having authored 87 papers that have together received 2.4k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (22 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers), Statistical Methods in Clinical Trials (14 papers), Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (13 papers), Dementia and Cognitive Impairment Research (12 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers) and Cancer Treatment and Pharmacology (8 papers). The work is most often cited by research in Biological Psychiatry (82 citations), Oncology (778 citations), Physiology (691 citations), Cancer Research (307 citations) and Pulmonary and Respiratory Medicine (588 citations). Paul Delmar has collaborated with scholars based in Switzerland, United Kingdom and United States. Frequent co-authors include Eric Van Cutsem, Sanne de Haas, Stefan Scherer, Paulo Fontoura, Gregory Klein, Carsten Hofmann, Mirjana Andjelković, Niall C. Tebbutt, Atsushi Ohtsu and Bernd Langer. Their work appears in journals such as Alzheimer s & Dementia, European Journal of Cancer, Neurology, Journal of Thoracic Oncology and Pharmaceutical Statistics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact